Answers are grounded in this paper and cite their sources.
The prevalence of early-onset colorectal cancer during the previous 20 years (EOCRC diagnosed before 50 years of age) has doubled in several countries, and its causes are still mostly unknown. There is mounting evidence that early life exposure to colibactin, a genotoxin generated by Escherichia coli strains containing the polyketide synthase (pks) island, can be mutagenic. The discovery and chemistry of colibactin and the experimental evidence that it leaves a distinctive mutational signature (SBS88/ID18) are summarized in this article. These markers were enriched in early onset illness (3.3 times more common in patients diagnosed before 40 than those older than 70) and imprinted early in tumor formation according to a seminal 2025 analysis of 981 colorectal cancer genomes from 11 nations. The emerging prevalence conundrum, translational techniques (ClbP inhibition, anti-adhesion, engineered neutralization, and probiotic safety), and the safety and effectiveness of therapies are then reviewed, along with clinical prevalence investigations that include data from Iraq. E. Coli that produces colibactin provides a unique, mechanistically defined link between a gut microbe and human cancer as well as the new "windows of opportunity" model of exposure. Lastly, we list the main information gaps, which include the early-stage prevalence conundrum, population coverage, timing and acquisition of exposure, causal proof in people, and the safety and effectiveness of therapies. Colibactin-producing E. coli provides a plausible method for prevention as well as a rare, mechanistically specific connection between a gut bacterium and human cancer.
No takes yet. Share an insight, caveat, or question.
Sara Ayad Ahmed (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: